INTRODUCTION
Human urotensin II (Glu-Thr-Pro-Asp-Cys-Phe-Trp-Lys-TyrCys-Val ; U-II) is a cyclic undecapeptide shown to have potent vasoactive effects [1] . Although the peptide had originally been isolated from urophysis (a neurosecretory organ of teleost fish found on the ventral aspect of the distal end of the spinal cord) [2] , the cDNA encoding its precursor has now been sequenced from many species [3] [4] [5] . In situ hybridization and immunohistochemistry have revealed that U-II is localized to the medulla oblongata of the brain and the spinal cord in the central nervous system, but is also present in such tissues as adrenal glands, kidney and spleen, suggesting neurohormonal or hormonal properties [3, 6] . Although it is clear that U-II influences the physiological regulation of mammalian cardiovascular function, early reports led to conflicting vasoactive responses depending on species or tissues used [7, 8] . Recent papers, however, have described how human U-II has potent vasodilator and cardiostimulant responses in human tissues [8, 9] .
Several structural forms of the peptide have been reported in various species of fish and amphibians, with a variation in primary structure occurring in the first five to seven residues of the N-terminus [10] . However, the C-terminal cyclic hexapeptide is conserved across species, and structure-activity studies on goby (Gillichthys mirabilis) U-II suggested that residues 6-12 (corresponding to amino acids 4 -11 in human) are sufficient for high-affinity binding to the receptor and to exert its biological activity [11] . More recently, an extensive structure-activity study of human U-II [12] has confirmed the importance of the human cyclic hexapeptide sequence for receptor activation. Moreover, similar activation levels attained by U-II peptides derived from various species (human, frog, fish and pig) have revealed that N-terminal residues might contribute to a lesser extent to the agonistic properties of the ligand [13] than the conserved portion of U-II consisting of residues Asp%-Val"" [11] .
Recently, it has been shown that U-II is the endogenous ligand of a G-protein-coupled receptor (GPCR) [4] , which was isolated from a human genomic library [6] and which possessed high sequence similarity to GPR14, an orphan receptor identified in rat [14] and currently referred to as the U-II receptor. The rat U-II receptor belongs to class A, the rhodopsin-like family, of the peptide subfamily of GPCRs and is comprised of 386 residues (389 for the human U-II receptor) [4] . The receptor possesses two potential N-glycosylation sites in the N-terminal domain (Asn#* and Asn$$) and two cysteine residues in the first and second extracellular loops, which are thought to participate in disulphide bonding. Intracellular portions contain the Glu\Asp-Arg-Tyr motif, which is well conserved amongst GPCRs, and potential phosphorylation sites are found in the cytoplasmic tail. The receptor is widely expressed in human tissues, the mRNA being found in the left atrium and ventricle of the heart and in smoothmuscle cells from the coronary artery and aorta as well as endothelial cells from several vascular beds [4] .
An understanding of the underlying molecular basis of how U-II binds and activates the U-II receptor is of key importance in the rational design of new pharmacophores. We have sought to probe into the putative interactions of the peptide with its cognate receptor by covalently modifying the U-II receptor with a photoreactive analogue of U-II containing the photoactivatable amino acid p-benzoyl--phenylalanine (Bz-Phe). The Bz-Phebased photoaffinity-labelling approach [15] has been successfully employed to identify binding sites in several peptide receptors [16] [17] [18] . Here we report on the specific interaction of "#&I-labelled [Bz-Phe']U-II with residues Met")%\Met")& of the fourth trans-membrane domain of the rat U-II receptor. This is the very first study giving important insights into how U-II interacts with its receptor using a direct identification approach.
EXPERIMENTAL Materials
BSA, bacitracin, soybean trypsin inhibitor and CNBr were from Sigma. Protein N-glycosidase F (PNGase-F ; EC 3.5.1.52), staphylococcal V8 protease (EC 3.4.21.19) and endoproteinase Arg-C (Endo Arg-C ; EC 3.4.22.8) were from Roche Diagnostics. The cDNA clone of the rat urotensin II receptor (GPR14) subcloned in the mammalian expression vector pcDNA $ was kindly provided by Dr Brian O'Dowd (Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada). AMINE2 and culture media were obtained from Life Technologies (Gaithersburg, MD, U.S.A.). U-II peptides were synthesized in our laboratories using Fmoc (fluoren-9-ylmethoxycarbonyl)-protected amino acids and Wang resin (a p-benzyloxybenzyl alcohol resin from Novabiochem, Laufelfingen, Switzerland). Cysteine residues were protected by acetamidomethyl groups, which were removed by using mercury acetate. Disulphide-bond formation was achieved by oxidation with DMSO [19] . The synthetic peptides were purified to homogeneity by reverse-phase HPLC. "#&I-U-II and "#&I-[Bz-Phe']U-II (sp. radioactivity 1000 Ci\mmol) were prepared with IODO-GEN2 (1,3,4,6-Tetrachloro-3a,6a-diphenylglycoluril ; Pierce Chemical Co.) as described by Fraker and Speck [20] . Briefly, 25 µl of 1 mM peptide solution was incubated with 50 µg of IODO-GEN2, 65 µl of 100 mM borate buffer, pH 8.5, and 1 mCi of Na"#&I for 30 min at room temperature before being purified by HPLC on a C-18 column. The specific radioactivity of the labelled peptides was determined by self-displacement and saturation-binding analysis.
PCR mutagenesis
Mutant receptor cDNAs were constructed by oligonucleotidedirected mutagenesis (Expand High Fidelity PCR System ; Roche Diagnostics) using the rat GPR14 as template. Two sets of forward and reverse oligonucleotides were constructed to introduce mutations simultaneously at both Met")% and Met")&. PCR products were re-inserted in pcDNA $ and mutagenesis was confirmed by nucleotide sequencing.
Cell culture and transfections
COS-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10 % (v\v) fetal-bovine serum, 100 i.u.\ml penicillin and 100 µg\ml streptomycin at 37 mC. Semi-confluent cells (70 %) in 100-mm-diameter Petri dishes were transfected using the AMINE2 method (Gibco BRL). Transfected cells were grown for 48 h before photoaffinity labelling and binding assays.
Binding experiments
COS-7 cells were washed once with PBS and subjected to one freeze-thaw cycle. Broken cells were then gently scraped into washing buffer [20 
Measurement of agonist-induced production of inositol phosphates
Accumulation of inositol phosphates was determined essentially as described [21] , with the following modification. Production of inositol phosphates was induced with 100 nM U-II and [BzPhe']U-II or 10 µM [Bz-Phe(]U-II and [Bz-Phe""]U-II for 20 min at 37 mC in buffer containing 10 mM LiCl. Inositol phosphates were sequentially eluted from the anion-exchange column by the addition of an ammonium formate\formic acid solution of increasing ionic strength. Fractions containing inositol phosphates were collected and counted for radioactivity in a liquidscintillation counter.
Photoaffinity labelling
Photoaffinity labelling was perfomed as previously described [16] . Transfected COS-7 cells were incubated for 1 h at room temperature in 0.5 ml of binding buffer containing the photoreactive radioligand (5 nM), in the presence or absence of U-II, angiotensin II (AngII) or endothelin-1 (ET-1). Cells were then washed, irradiated for 1 h at 0 mC under filtered UV light in washing buffer and centrifuged. The pellet was solubilized in modified radioimmunoprecipitation buffer [' m-RIPA ' ; 100 mM Na # HPO % (pH 8.5)\25 mM EDTA\0.1 mg\ml soybean trypsin inhibitor\1 % (v\v) Nonidet P40] containing Complete Protease Inhibitor Cocktail2 (Roche Diagnostics). After centrifugation (13 000 g for 30 min at 4 mC), the supernatants were kept at k80 mC until further analysis.
Partial purification of the labelled complex
Photolabelled receptors were partially purified as previously described [16, 22] . Briefly, photolabelled receptors were seperated by SDS\PAGE before being dried and exposed to BioMax2MS films (Kodak). Bands corresponding to receptor-ligand complexes were cut from the gels and submitted to passive elution. Eluted proteins were then concentrated, divided into portions and kept at k20 mC.
Endoglycosidase, proteolytic and chemical digestions
For endoglycosidase digestions, partially purified photolabeled receptors were resuspended in digestion buffer containing 0.5 % Nonidet P40. PNGase-F (500 units\ml) was added, and samples were incubated at room temperature for 16 h. For proteolytic digestions, partially purified photolabelled receptors (5000-10 000 c.p.m.) were resuspended in 25 µl of digestion buffer [100 mM NH % HCO $ (pH 8.0)\0.1 % SDS] and were incubated for 5-7 days at room temperature. Under these conditions V8 protease cleaves at the C-terminal side of glutamate residues. For Endo Arg-C digestion, partially purified photolabelled receptors (5000-10 000 c.p.m.) were resuspended in 75 µl of digestion buffer (containing 90 mM Tris\HCl, pH 7.6, 8.5 mM CaCl # , 5 mM dithiothreitol, 0.5 mM EDTA and 0.01 % SDS) and samples were incubated for 16 h at 37 mC. When subsequent digestions were needed, products of the first digestion were run on a 16.5 % (w\v) acrylamide\Tris\Tricine gel and the corresponding band was eluted in water containing 0.1 % SDS. Eluted proteins were Peptide-binding domain of the urotensin II receptor freeze-dried and submitted to subsequent digestion. For CNBr hydrolysis, partially purified photolabelled receptors (5000-10 000 c.p.m.) were resuspended in a 1 : 1 mixture of 50 % trifluoroacetic acid and CNBr (200 mg\ml) and incubated at room temperature, in the dark for 18 h. Reactions were terminated by adding 1 ml of water and the material was freeze-dried.
Figure 1 (A) Amino acid sequence of hU-II and photoreactive hU-II analogues and (B) two-dimensional representation of the primary structure of the rat U-II receptor and its potential cleavage sites by specific proteases and CNBr

Analysis of the products of proteolysis and chemical cleavage
The products of proteolysis and chemical cleavage were analysed by SDS\PAGE using 16.5 % polyacrylamide\Tris\Tricine gels, followed by autoradiography on X-ray films (Kodak BioMax2 MS) with intensifying screens. "%C-Labelled low-molecular-mass protein standards (Amersham Biosciences) were used to determine apparent molecular masses. 
RESULTS
Binding specificity and functional properties of photoreactive analogues
Photoaffinity labelling of rat U-II receptor
In photoaffinity-labelling experiments using "#&I-[Bz-Phe']U-II, two proteins migrating as 60 and 31 kDa bands on SDS\PAGE were specifically and covalently labelled (Figure 2A) . The labelling of these forms of the U-II receptor was decreased in a dose-dependent manner (Figure 2A) with complete abolition at 100 µM UII (Figures 2A and 2B, lanes 2) . No decrease in labelling of either form was observed when AngII (100 µM) ( Figure 2B specificity and the selectivity of the labelling. Determination of covalent incorporation yields, calculated from the ratio of total radioactivity found in isolated bands to total specific binding observed before photolysis, revealed that "#&I-[Bz-Phe']U-II had a 60% yield of covalent incorporation on to the U-II receptor.
Deglycosylation of the ligand-receptor complexes
To verify whether the two receptor forms labelled by "#&I-[BzPhe']UII were glycosylated, both the 60 and the 31 kDa complexes were partially purified and submitted to PNGase-F digestion (Figure 3) . Deglycosylation of the 60 kDa ligandreceptor complex led to the production of a 42 kDa band ( Figure  3A , lane 2), corresponding to the calculated molecular mass of the U-II receptor. However, deglycosylation of the 31 kDa complex did not lower its molecular mass, suggesting its unglycosylated nature ( Figure 3B, lane 2) .
V8-protease digestion of the 60 kDa 125 I-[Bz-Phe 6 ]U-II-U-II receptor complex
In an initial attempt to map the ligand-receptor contact sites, the 60 kDa photoligand-receptor complex was partially purified ( Figure 4A , lane 1) and submitted to V8-protease digestion, which cleaves on the C-terminal side of glutamate residues ( Figure 1B) . This digestion produced a band of apparent molecular mass 17 kDa ( Figure 4A, lane 2) . Two potential receptor domains appear as potential candidates : one comprising receptor domain Leu#%-Glu"%(, with a calculated molecular mass of 14.8 kDa, which is glycosylated on Asn#* and\or Asn$$ residues ( Figure 1B) , and another fragment corresponding to Arg"%)-Glu#)', with a calculated molecular mass of 17.5 kDa (unglycosylated). Since PNGase-F digestion did not change the migration pattern of the latter fragment (results not shown), this suggested the absence of N-glycosylation on this fragment. The only candidate fragment is the 139-residue polypeptide encompassing Arg"%) to Glu#)' ( Figure 4B ).
Endo Arg-C digestion of the 60 kDa 125 
I-[Bz-Phe 6 ]U-II-U-II receptor complex
To further identify the binding domain, the 60 kDa photoligandreceptor complex was submitted to Endo Arg-C digestion, which specifically cleaves at the C-terminal end of arginine residues ( Figure 1B) . Endo Arg-C digestion ( Figure 5A , lane 1) produced two bands migrating at a molecular mass of 6 kDa and 4 kDa ( Figure 5A, lane 2) . Since the 6 kDa band is progressively cleaved to give the 4 kDa band after prolonged digestion times (results not shown), the former is believed to originate from a partial enzyme cleavage. Thus it is assumed that the labelling occurs only on one receptor site, the smallest region corresponding to the 4 kDa Arg-C-generated fragment. Taking this into consideration with those results obtained with the V8 protease circumscribing the labelling to the 148-286 polypeptide, three fragments appear as potential candidates : Val"#&-Arg"%) (4.2 kDa) (if labelling occurred exclusively on Arg"%)) ; Lys"'(-Arg"*# (4.4 kDa) ; Thr#"!-Arg#$$ (4.0 kDa) ( Figure 5C ).
Labelling occurs exclusively in the fourth transmembrane domain of the U-II receptor
In order to discriminate between the three possible domains of interaction identified by Endo Arg-C digestion as being the third, fourth or the fifth transmembrane domain, we took advantage of the exclusive presence of methionine residues (positions 184 -185) within the Lys"'(-Arg"*# receptor domain. Of the three potential Endo-Arg-C-generated fragments, only the 167-192 polypeptide would be CNBr-sensitive, enabling us to identify it from the other two. We then proceeded to cleave the 4 kDa fragment previously generated by Endo Arg-C with CNBr. An adduct of 2.5 kDa migrating with the dye front was obtained ( Figure 5B ). Given the low resolution of this part of the gel, it could only be determined that the fragment was sensitive to CNBr cleavage. Thus, on the basis of CNBr-sensitivity, we can attribute the labelling as occurring exclusively in the fourth transmembrane domain of the receptor ( Figure 5C ).
I-[Bz-Phe 6 ]U-II interacts with Met 184 and/or Met 185 of the U-II receptor
To further confirm the identity of the receptor domain interacting with the photoligand, the "#&I-[Bz-Phe']U-II-U-II receptor complex was digested with V8 protease and the 17 kDa fragment was partially purified. Cleavage of this fragment with CNBr ( Figure  6A , lane 1) led to the production of three distinct labelled fragments of 12.5, 6.5 and of 2 kDa ( Figure 6A, lane 2) , the latter co-migrating with the free ligand of calculated molecular mass 1.5 kDa ( Figure 6A, lane 3) . The labelled fragments able to produce this pattern are indicated in Figure 6 (B). The 12.5 and 6.5 kDa entities would be the result of partial CNBr cleavage at Met")% or Met")&, yielding fragments corresponding to Met")&-Glu#)' (13 kDa) and Arg"%) − -[Met")%\")&] (5.8 kDa). The 2 kDa fragment could either correspond to Met")& covalently attached to the ligand or the ligand itself released from one or both methionine residues following CNBr treatment [23] . This led us 
Effect of photolabelling on methionine double mutants at positions 184 and 185 of the U-II receptor
Since the photolabelling results on the wild-type receptor suggested that Met")% and\or Met")& interacted with U-II at position 6, we examined the effect of replacing these two residues with leucine or alanine by constructing the M184L\M185L and M184A\M185A U-II receptor mutants. The integrity and functionality of these receptors were assessed pharmacologically. M185A was then performed to verify the effect of side-chain modification on the yield of covalent incorporation of "#&I-[Bz-Phe']U-II. Determination of covalent incorporation yields (calculated from the ratio of total radioactivity found in isolated bands to total specific binding observed before photolysis) revealed yields evaluated at 70 % (M184L\M185L) and 40 % (M184A\M185A) when compared with the wild-type receptor ( Figure 7A) . Indeed, the intensity of labelling of both mutant receptors is clearly weaker than that of wild-type receptor. This further demonstrates that Met")% and Met")& are critical for the covalent insertion of the photoligand.
We then proceeded to verify whether modifying the mutant receptors still enabled binding of the photoligand in the same region as that in the wild-type receptor. V8-protease digestion of the ligand-mutant receptor complexes produced a 17 kDa fragment similar to that of the wild-type receptor, which showed that the labelling on both mutant receptors still occurred in the Arg"%)-Glu#)' domain of the mutated U-II receptors ( Figure 7B ). Furthermore, CNBr cleavage of the whole ligand-mutant receptor complexes failed to show any ligand release, in contrast with the wild-type receptor, since only a 17 kDa fragment is produced along with a partial digestion product of 25 kDa ( Figure 7C ). Since CNBr-cleavage-sensitive methionine residues at the site of photoattachment are absent in both leucine and alanine double mutants of the receptor, the smaller fragment of 17 kDa would correspond to Ser"%&-Met#)). importance in order to understand the initial steps leading to receptor activation. In the present study, photoaffinity labelling was used as a strategy to probe into the interactions of the newly described ligand-receptor pair of U-II-U-II receptor. This approach depends on the spatial proximity between a radioactive photoligand and receptor domains to form a covalent conjugate that is subsequently mapped to identify the interaction sites. As a preliminary step, three analogues of U-II, containing Bz-Phe substituted at positions 6, 7 and 11, were prepared and characterized for their capacity to recognize and activate the U-II receptor. The physico-chemical properties of the Bz-Phe moiety, hydrophobic and aromatic, are also shared by residues 6 (Phe) and 7 (Trp), while residue 11 (Val) retains a hydrophobic nature. Although all three photoreactive analogues were able to stimulate phospholipase C-dependent production of the second messenger Ins(1,4,5)P $ , suggesting their agonistic nature, [Bz-Phe(]U-II and [Bz-Phe""]U-II had poor binding affinities to the receptor. However, [Bz-Phe']U-II recognized the receptor with a 5-fold higher affinity than U-II itself. Report have shown that modifications of human U-II at positions 6 and 11 are well tolerated, while a change at position 7 greatly impairs the peptide's binding properties [12] . It has been suggested that the presence of a hydrophobic amino acid at the C-terminus, as well as at positions occupied by phenylalanine and tryptophan, of U-II is crucial to the peptide's ability to interact with its receptor and to its capacity at producing biological effects. In NMR and dynamic simulated annealing studies of the solution conformation of U-II, the Phe', Trp( and Val"" side chains were oriented on the same side of the molecule so as to form a hydrophobic pocket optimized for binding with its receptor [24] . Obviously, Bz-Phe substitution at Trp( and Val"" greatly altered the binding properties of the peptide, possibly by the enhanced steric hindrance effect caused by the Bz-Phe moiety with the receptor's binding pocket. Thus, based on its affinity and its capacity at stimulating the U-II receptor, it is reasonable to suppose that [Bz-Phe']U-II adopts a binding mode similar to that taken by U-II itself.
DISCUSSION
In photolabelling experiments performed in transfected COS-7 cells, [Bz-Phe']U-II specifically labelled the U-II receptor, which migrated as two entities, one of molecular mass $ 60 kDa and another of molecular mass $ 31 kDa. The susceptibility of the 60 kDa protein to PNGase-F treatment suggests the glycosylated nature of the receptor, a feature that would cause its molecular mass to be overestimated. This behaviour on SDS\ PAGE has been observed for other glycosylated GPCRs, such as the Ang II receptors AT " and AT # [22, 25] . The result further implies that the 60 kDa form corresponds to the complete receptor. Because of its insensitivity to PNGase treatment, the 31 kDa protein may originate from the intact complex lacking an N-terminal portion. It is still not clear whether this fragment is produced during the experimental procedure after binding has occurred or before binding at the cell surface, but we have observed similar photolabelling patterns using various transfected cell lines (results not shown).
Results from enzymic and chemical degradation of the photoligand-receptor complex clearly identify Met")% and Met")& as contact points for "#&I-[Bz-Phe']U-II. Our results first showed that the labelling was restricted to the fourth transmembrane domain of the U-II receptor. A 2 kDa fragment was also produced following CNBr cleavage of the 17 kDa V8-proteasegenerated fragment, thus suggesting photoligand release from methionine residues [23] . Also, mutation of the photoattachment site gives further support to ligand interaction with the methionine residues. Indeed, the significant decrease in labelling yields of the M184L\M185L and M184A\M185A receptor mutants further reinforces the idea of the methionine residues as important ligand contact points. Furthermore, the absence of the 2 kDa adduct following CNBr cleavage of the two receptor mutants clearly demonstrate that the original photoattachment site has been abolished.
Thus photolabelling coupled with mutational studies strongly suggest that transmembrane 4 participates in the bimolecular ligand-receptor complex interface and contributes to hormone binding. Here, we report a close proximity between an aromatic benzophenone amino acid of the ligand and methionine residues of the receptor to describe a ligand-receptor interaction. Identification of methionine residues as contact points in receptors have been frequently reported in labelling studies employing the benzophenone moiety [18, 26] . This type of interaction appears to be favoured, since the photogenerated benzophenone radical forms a transient charge-transfer complex with the sulphur atom in the methionine residue, followed by a covalent C-H insertion into the sulphur-adjacent γ-methylene or ε-methyl group of methionine [15] . The increased rate of reaction of benzophenone radicals with thioether moieties would cause a pronounced selectivity towards methionine residues in a protein environment. The reactivity distance between the benzophenone radical and a methionine residue could increase the normal reactivity radius of Bz-Phe [27] .
Recent data report significant reductions in photolabelling efficacy when replacing a native interacting methionine residue within the receptor with a related amino acid such as leucine or when shortening side-chain lengths by substitution with alanine [28, 29] . Our results strongly suggest that Met")% and Met")& constitute important determinants of the U-II receptor binding pocket, but we cannot rule out the possibility that other receptor residues might also assist in accommodating Phe' of U-II in the binding pocket. Given the hydrophobic nature of the benzophenone side chain, the interactions depicted are likely to occur with hydrophobic receptor residues. However, this type of interaction does not always accurately reflect the true binding dynamics of the native ligand, but ensures identification of residues in close proximity to the targeted amino acid. A good example of this is provided in a recent study where Lys#( of parathyroid hormone was substituted by Bz-Phe, which linked to a leucine residue within the parathyroid-hormone receptor, while numerous glutamate residues were adjacent to the interaction site [18] . It was pointed out that the glutamate residues probably contributed extensively to the recognition process of the native ligand containing lysine [30] . Therefore, careful interpretation of the results should then be considered when assessing direct contact points.
Our results provide information as to the identification of those residues within the U-II receptor that participate in the interaction with the ligand, urotensin II. The superfamily of GCPRs is extensive and diverse, with ligands as varied as photons, odorants, biogenic amines, peptides and large glycoproteins. Our understanding of the bimolecular recognition process for small ligands such as biogenic amines is that they will interact with residues found within transmembrane domains [31] . Interaction of peptide ligands would appear to be more complex, with determinants being located within transmembrane domains as well as within extracellular loops. For example, Ang II adopts an extended structure when bound to its receptors (AT " and AT # ) due to interactions with residues of transmembrane domains and extracellular loops [16, 25, 27] . Studies on ligand-receptor interactions directed toward the vasopressin receptor V1a suggest a similar interaction mode, with the hydrophobic part of the peptide embedded in transmembrane domains while the more hydrophilic region positions itself in close contact with extracellular domains of the receptor [32] . However, despite different binding modes, GPCRs seem to follow a standard pathway leading to G-protein activation, a direct consequence of ligandinduced transmembrane movement. Indeed, various studies on rhodopsin and adrenoreceptors have demonstrated that significant transmembrane rotations occur following agonist binding [33, 34] .
The high-resolution structure of rhodopsin has provided very useful insights into the structure of GPCRs which, despite low sequence identity, possess similar topologies [35] . The receptor inactive state depicted by this high-resolution structure shows the second extracellular loop (ECL2) ' capping ' the 11-cisretinylidene-chromophore-binding pocket. It also has been reported that residues from ECL2 would contribute to the formation of the active form of rhodopsin, suggesting that this flexible domain might play an important role in the activation process [36] . Indeed, many GPCRs have been shown to bind their ligand through interactions mediated by the ECL2 or adjacent domains [37, 38] . Activation determinants located in ECL2 and leading to constitutive receptor signalling have also been reported among a subfamily of GPCRs [39] . Our results point to the important contribution of transmembrane domain 4 adjacent to ECL2 of the U-II receptor, in docking with residue 6 found within the highly conserved cyclic portion of U-II. Further studies combining both mutagenesis, photoaffinitylabelling approaches and molecular modelling will provide information crucial to the development of models defining the binding pocket of this receptor. Because of U-II's putative role in heart failure and other cardiovascular pathologies, the design of novel ligands could be facilitated by the knowledge brought on by these models.
